All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 8, 2023
Home » Topics » Private » Series B

Series B
Series B RSS Feed RSS

3D Euro symbol

Varmx adds €30M to series B, preps for pivotal testing of DOAC reversal agent

May 25, 2023
By Nuala Moran
No Comments
Varmx BV has raised €30 million (US$32 million) in an extension to its series B to fund preparations for the pivotal trial of VMX-C001, a modified recombinant factor X that acts as a universal antidote to reverse the effects of direct oral anticoagulants. The drug is intended for use in patients suffering severe spontaneous bleeding or needing emergency surgery.
Read More
Huang Baohua, founder and CEO, Coherent Biopharma

Coherent Biopharma nets $100M in financing for Bi-XDC drugs

May 23, 2023
By Doris Yu
No Comments
Coherent Biopharma Co. Ltd. raised $100 million in series B and B+ financing rounds to step up its efforts to develop its bi-targeting ligand-drug conjugate (Bi-XDC) drugs and get them to market. Suzhou, China-based Coherent plans to use its newly expanded war chest to support the clinical trials of three candidates, CBP-1008, CBP-1018 and CBP-1019, as well as an IND application for CBP-8008 in China and the U.S., the company told BioWorld.
Read More
Cross section of brain
Newco news

Nido Biosciences raises $109M to drug novel targets in neurological disease

May 15, 2023
By Cormac Sheridan
No Comments
Nido Biosciences Inc. emerged from stealth by unveiling $109 million in series A and B equity funding and a clinical-stage program in spinal and bulbar muscular atrophy.
Read More

Zephyrm nets ¥200M in financing to step up efforts in stem cell drug development

April 25, 2023
By Doris Yu
No Comments
Zephyrm Biotechnologies Co. Ltd. raised ¥200 million (US$29 million) in a series B financing to support phase I and II trials of the company’s human pluripotent stem cell candidates to treat lung diseases, degenerative joint diseases such as osteoarthritis, CNS diseases, inherited retinal degenerations and retinal degenerative diseases. The money will also be used for the construction of its technology platform and cell manufacturing bases.
Read More
Noah Medical

Flood of funding lifts Noah’s ark with $150M series B

April 19, 2023
By Annette Boyle
No Comments
Compared to recent fundraising rounds in the med-tech space, Noah Medical Inc. was veritably deluged with cash in its series B. Softbank Vision Fund and Prosperity7 Ventures led the round, which rained down $150 million on the medical robotics company. Other participants included Hillhouse, Sequoia China, Shangbay Capital, Uphonest Capital, Sunmed Capital, Lyfe Capital, 1955 Capital, AME Cloud Ventures and undisclosed strategic investors.
Read More

Zephyrm nets ¥200M in financing to step up efforts in stem cell drug development

April 19, 2023
By Doris Yu
No Comments
Zephyrm Biotechnologies Co. Ltd. raised ¥200 million (US$29 million) in a series B financing to support phase I and II trials of the company’s human pluripotent stem cell candidates to treat lung diseases, degenerative joint diseases such as osteoarthritis, CNS diseases, inherited retinal degenerations and retinal degenerative diseases. The money will also be used for the construction of its technology platform and cell manufacturing bases.
Read More
Neuromod patient using Lenire

Neuromod prepares to launch tinnitus treatment in the US after €30M raise

April 17, 2023
By Shani Alexander
No Comments
Neuromod Devices Ltd. will use the €30 million (US$ 32.78 million) financing it recently raised to launch its tinnitus treatment device, Lenire, in the U.S. where there are an estimated 50 million Americans suffering from tinnitus, CEO, Ross O’Neill, told BioWorld. “To get this financing closed is very exciting as we go into the U.S. market which is the biggest hearing market in the world,” he added.
Read More

Torl closes $158M series B to advance anti-Claudin candidates

April 14, 2023
By Caroline Richards
No Comments
Torl Biotherapeutics LLC has raised $158 million in a series B round as it seeks to nudge its anti-Claudin-6 antibody-drug conjugate candidates, TORL-123 and TORL-2307, beyond phase I trials for the treatment of ovarian and gastric cancers, respectively. Claudin-6, or CLDN6, is a molecule that forms tight junctions around cells. It is highly expressed in a range of solid tumor types, so is a popular target for drug development.
Read More
Microscopic view of of high grade urothelial carcinoma of the ureter in a man.
Cancer

Flare Therapeutics announces financing to fund work targeting novel transcription factors

March 23, 2023
No Comments
Flare Therapeutics Inc. has announced a US$123 million series B financing to support its work targeting novel transcription factors for cancer and other diseases.
Read More
Bladder cancer illustration

$123M: Series B round ignites Flare Therapeutics program in urothelial cancer

March 22, 2023
By Cormac Sheridan
No Comments
Flare Therapeutics Inc. raised $123 million in an oversubscribed series B round to take its lead compound, FX-909, a potentially first-in-class peroxisome proliferator-activated receptor gamma inhibitor, into clinical trials in patients with advanced urothelial cancer and to advance additional pipeline candidates acting on other transcription factor targets with genetically validated links to disease biology.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 30 31 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 7, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 8, 2023.
  • Medical cannabis in blister pack of capsules

    Zelira’s stock triples as cannabinoid outperforms Lyrica in pain

    BioWorld
    Medicinal cannabis company Zelira Therapeutics Ltd.’s stock shot up 224% on May 31 on the heels of news that its cannabinoid product, ZLT-L-007, outperformed...
  • Cerebellum, brain stem, spinal cord

    Reprocell reports mixed results for phase II Stemchymal trial in spinocerebellar ataxia

    BioWorld
    Regenerative medicine product Stemchymal, an allogeneic adipose-derived mesenchymal stem cell treatment, missed the primary efficacy endpoints in two phase II...
  • Breast cancer illustration

    ASCO 2023: Novartis and Lilly make progress in early breast cancer treatments

    BioWorld
    Positive data from two studies treating early breast cancer with CDK4/6 inhibitors presented at the American Society of Clinical Oncology (ASCO) meeting in...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing